Multiple sclerosis (Houndmills, Basingstoke, England)
Cardiogenic shock after ocrelizumab infusion in relapsing-remitting multiple sclerosis.
Giulia De Napoli, Enrico Gotti, Chiara Baldovini, Luisa Di Sciascio, Francesca Vitetta, Krzysztof Smolik, Martina Cardi, Diana Ferraro
Published: 202510.1177/13524585251407501
Abstract
A 42-year-old man with relapsing-remitting multiple sclerosis and no prior cardiac history developed a severe but reversible left ventricular systolic dysfunction following ocrelizumab administration. Symptoms started 24-36 hours after the infusion a…
Preview only. Read the full abstract at the source